Sanofi (SNY) Stock: Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 13, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: None
Big funds13F, quarter ended Jun 30, 2026: 4 added, 0 cut
Federal contractsUSAspending.gov, 12 months: 10+ awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about SNY filings

Are insiders buying or selling Sanofi ADR (SNY) stock?

Neither. Sanofi ADR (SNY) insiders filed no open-market purchases or sales in the 90 days to Nov 13, 2026, according to SEC Form 4 filings.

Which members of Congress have traded SNY recently?

None. No member of Congress disclosed a SNY trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this SNY smart-money data?

This summary uses filings available on Nov 13, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

13F: filed up to 45 days late.

Smart money on SNY

Lean long1 source:
- Funds

Top traders
No tracked positions at the last update
Insiders
No recent insider filings found
Congress
No recent politician filings found
Funds
Lean long3 added · 0 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Influencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about SNY filings

Are insiders buying or selling Sanofi ADR (SNY) stock?

Neither. Sanofi ADR (SNY) insiders filed no open-market purchases or sales in the 90 days to Nov 13, 2026, according to SEC Form 4 filings.

Which members of Congress have traded SNY recently?

None. No member of Congress disclosed a SNY trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this SNY smart-money data?

Funds

What funds are doing

4 moves · 6 mo

Buys/Adds$131.2M

Buys/Adds (3)

BA
Balyasny
Dmitry Balyasny · Q2 2026 13F
$62.5M
added
Signals like this: n=13773, 53% finished lower at D15, median -0.4% vs SPY -0.4%
P7
Point72
Steven Cohen · Q2 2026 13F
$35.0M
bought
Signals like this: n=3228, 54% finished lower at D15, median -0.8% vs SPY -0.4%
QR
Qube Research
Q2 2026 13F
$27.1M
bought

1 more moves

Pro opens all of them for $16.50/month, paid yearly.

Unlock all 1 moves

Other smart money signals

Activist stakes, short interest & more

2 items

F1
Filing 13d GLight
Amundi filed SC 13G/A on Sanofi (passive 5.70% stake)
SI
Short Interest ChangeModerate
short-volume tape softening: latest 12.8% fell 11.4pp vs 19d avg 24.2%

Unlock everything for $29/month

Unlock for $29/month

Reported Oct 30, 2026

Earnings came in 25.2% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Oct 30, 2026

Period ending

Sep 30, 2026

Earnings per share

$2.04+25.15% beat

$1.63 expected

Revenue

EUR 15.23B

Financial statements: Alpha Vantage

Next report

What the street expects next

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Oct 30, 2026	$2.04est. $1.63	+25.15%beat	EUR 15.23BAlpha Vantage	+15.7%from EUR 13.17B
Jun 30, 2026Reported Jul 30, 2026	$1.21est. $1.10	+10.00%beat	EUR 12.30BAlpha Vantage	+14.6%from EUR 10.73B
Mar 31, 2026Reported Apr 23, 2026	$1.10est. $1.03	+6.80%beat	EUR 11.24BAlpha Vantage	+6.0%from EUR 10.61B
Dec 31, 2025Reported Jan 29, 2026	$0.91est. $0.85	+7.06%beat	EUR 12.21BAlpha Vantage	+59.9%from EUR 7.63B
Sep 30, 2025Reported Oct 24, 2025	$1.69est. $1.57	+7.64%beat	EUR 13.17BAlpha Vantage	-7.0%from EUR 14.16B
Jun 30, 2025Reported Jul 31, 2025	$0.91est. $1.00	-9.00%miss	EUR 10.73BAlpha Vantage	-5.7%from EUR 11.38B
Mar 31, 2025Reported Apr 24, 2025	$1.02est. $0.95	+7.37%beat	EUR 10.61BAlpha Vantage	+9.0%from EUR 9.73B
Dec 31, 2024Reported Jan 30, 2025	$0.68est. $0.74	-8.11%miss	EUR 7.63BAlpha Vantage	-37.5%from EUR 12.20B

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $47.61
High: $48.46
Low: $47.52
Prev close: $48.23
52-wk high: $49.90
52-wk low: $39.07
Mkt cap: $116.04B
P/E: 24.1x
ROE: +5.7%
Fwd P/E: 9.2x
Beta: 0.26
P/S: 2.3x
P/B: 1.4x
Profit margin: +8.2%
Op margin: +22.3%

Fundamentals

Is the business strong?

Reasonably priced and running thin margins.

Net margin: 8.2%
P/E: 24.09
Forward P/E: 9.18
Market cap: $116.0B

Valuation

P/S2.28
P/B1.42
Dividend yield0.0%

Quality

Operating margin22.3%
ROE5.7%
ROA5.5%

Growth

Beta0.26

Technicals

Price structure

This stock is in a strong uptrend, and looks overbought after a fast run-up.

Trend

Strong uptrend

85 / 100

RSI 14

87overbought

20D volatility

30%annualized

52-week range

$48.43

$39.07$49.90

20D support

$39.51recent floor

20D resistance

$48.67recent ceiling

Returns

5D +2.0%20D +21.8%60D +7.7%

Price vs moving averages

SMA20 +10.5%SMA50 +13.9%SMA200 +11.3%

Volume pace

1.44xvs prior 20D

News

What the news says

21 articles · 7 days

Coverage leans bullish

10 bullish · 5 neutral · 6 bearish

Sanofi Uses Movement and Music to Step Ahead of Type 1 Diabetes — LBB
BullishNov 10
Sanofi Takes €4.7b Statutory Profit Hit on Unusual Items
NeutralNov 10
Sanofi-backed Windward breezes toward $204M IPO to fund respiratory pipeline from China
Leans bullishNov 9
The 45-Minute Study Build and Sanofi’s Push to Automate Clinical Trials
NeutralNov 9
Sanofi upgraded by BNP Paribas Exane
BullishNov 9
StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate
Leans bearishNov 9
Sanofi stops development of Nurix-partnered immune drug
Leans bearishNov 4
NRIX Stock Clocks Worst Day Ever After Sanofi Discontinues Trial Of Licensed Drug: Wells Fargo Slashes Price Target
Leans bearishNov 4

11 macro signals shaping SNY right now

Unlock sector rotation, regime shifts, and macro event windows tied to this stock.

Unlock the full results

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Sep 30, 2026Oct 30, 2026

$2.04est. $1.63

+25.15%

EUR 15.23BAlpha Vantage

+15.7%from EUR 13.17B

Jun 30, 2026Jul 30, 2026

$1.21est. $1.10

+10.00%

EUR 12.30BAlpha Vantage

+14.6%from EUR 10.73B

Mar 31, 2026Apr 23, 2026

$1.10est. $1.03

+6.80%

EUR 11.24BAlpha Vantage

+6.0%from EUR 10.61B

Dec 31, 2025Jan 29, 2026

$0.91est. $0.85

+7.06%

EUR 12.21BAlpha Vantage

+59.9%from EUR 7.63B

Sep 30, 2025Oct 24, 2025

$1.69est. $1.57

+7.64%

EUR 13.17BAlpha Vantage

-7.0%from EUR 14.16B

Jun 30, 2025Jul 31, 2025

$0.91est. $1.00

-9.00%

EUR 10.73BAlpha Vantage

-5.7%from EUR 11.38B

Mar 31, 2025Apr 24, 2025

$1.02est. $0.95

+7.37%

EUR 10.61BAlpha Vantage

+9.0%from EUR 9.73B

Dec 31, 2024Jan 30, 2025

$0.68est. $0.74

-8.11%

EUR 7.63BAlpha Vantage

-37.5%from EUR 12.20B

Sanofi ADR

Smart money at a glance

What do analysts expect?

Questions about SNY filings

Smart money on SNY

Questions about SNY filings

What funds are doing

How top traders are positioned

Activist stakes, short interest & more

Unlock everything for $29/month

Earnings came in 25.2% above what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

What the news says

Ask it in Claude or ChatGPT.

Sanofi ADR

Smart money at a glance

What do analysts expect?

Questions about SNY filings

Smart money on SNY

Questions about SNY filings

What funds are doing

How top traders are positioned

Activist stakes, short interest & more

Unlock everything for $29/month

Earnings came in 25.2% above what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

What the news says

Ask it in Claude or ChatGPT.

Sanofi ADR

Overview

Questions about SNY filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

News

Macro

Ask it in Claude or ChatGPT.

Sanofi ADR

Overview

Questions about SNY filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

News

Macro

Ask it in Claude or ChatGPT.